197 related articles for article (PubMed ID: 38790661)
1. Modeling Melanoma Heterogeneity In Vitro: Redox, Resistance and Pigmentation Profiles.
Carvalho LADC; Noma IHY; Uehara AH; Siena ÁDD; Osaki LH; Mori MP; Pinto NCS; Freitas VM; Junior WAS; Smalley KSM; Maria-Engler SS
Antioxidants (Basel); 2024 Apr; 13(5):. PubMed ID: 38790661
[TBL] [Abstract][Full Text] [Related]
2. Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.
Ahmed F; Haass NK
Front Oncol; 2018; 8():173. PubMed ID: 29881716
[TBL] [Abstract][Full Text] [Related]
3. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
[TBL] [Abstract][Full Text] [Related]
4. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G
J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850
[TBL] [Abstract][Full Text] [Related]
5. Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors.
Khamari R; Trinh A; Gabert PE; Corazao-Rozas P; Riveros-Cruz S; Balayssac S; Malet-Martino M; Dekiouk S; Joncquel Chevalier Curt M; Maboudou P; Garçon G; Ravasi L; Guerreschi P; Mortier L; Quesnel B; Marchetti P; Kluza J
Cell Death Dis; 2018 Feb; 9(3):325. PubMed ID: 29487283
[TBL] [Abstract][Full Text] [Related]
6. Prdx1 Interacts with ASK1 upon Exposure to H
Vo TN; Malo Pueyo J; Wahni K; Ezeriņa D; Bolduc J; Messens J
Antioxidants (Basel); 2021 Jun; 10(7):. PubMed ID: 34209102
[TBL] [Abstract][Full Text] [Related]
7. Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells.
Ross KC; Andrews AJ; Marion CD; Yen TJ; Bhattacharjee V
Mol Cancer Ther; 2017 Aug; 16(8):1596-1609. PubMed ID: 28500236
[TBL] [Abstract][Full Text] [Related]
8. Increased IRF9-STAT2 Signaling Leads to Adaptive Resistance toward Targeted Therapy in Melanoma by Restraining GSDME-Dependent Pyroptosis.
Wang D; Fu Z; Gao L; Zeng J; Xiang Y; Zhou L; Tong X; Wang XQ; Lu J
J Invest Dermatol; 2022 Sep; 142(9):2476-2487.e9. PubMed ID: 35148998
[TBL] [Abstract][Full Text] [Related]
9. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
[TBL] [Abstract][Full Text] [Related]
10. Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program.
Czyz M; Sztiller-Sikorska M; Gajos-Michniewicz A; Osrodek M; Hartman ML
J Oncol; 2019; 2019():1697913. PubMed ID: 31354817
[TBL] [Abstract][Full Text] [Related]
11. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
13. Targeting of PDGF-C/NRP-1 autocrine loop as a new strategy for counteracting the invasiveness of melanoma resistant to braf inhibitors.
Ruffini F; Ceci C; Atzori MG; Caporali S; Levati L; Bonmassar L; Cappellini GCA; D'Atri S; Graziani G; Lacal PM
Pharmacol Res; 2023 Jun; 192():106782. PubMed ID: 37127213
[TBL] [Abstract][Full Text] [Related]
14. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
15. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
16. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
[TBL] [Abstract][Full Text] [Related]
17. Dynamical modeling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity.
Subhadarshini S; Sahoo S; Debnath S; Somarelli JA; Jolly MK
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678920
[TBL] [Abstract][Full Text] [Related]
18. Redox-stress response resistance (RRR) mediated by hyperoxidation of peroxiredoxin 2 in senescent cells.
Meng J; Wang Y; Lv Z; Qiao X; Ye A; Zhu Q; Chen C
Sci China Life Sci; 2023 Oct; 66(10):2280-2294. PubMed ID: 37160651
[TBL] [Abstract][Full Text] [Related]
19. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
20. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway.
Rathore M; Girard C; Ohanna M; Tichet M; Ben Jouira R; Garcia E; Larbret F; Gesson M; Audebert S; Lacour JP; Montaudié H; Prod'Homme V; Tartare-Deckert S; Deckert M
Oncogene; 2019 Jul; 38(30):5873-5889. PubMed ID: 31253871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
